Case Studies

AI & Diagnostic Accuracy: The Multi-Sector Revolution

As hospitals look toward the future, the role of Artificial Intelligence must be viewed as part of a global paradigm shift. AI is no longer a localized experiment; it is the core engine transforming Autonomous Systems, Manufacturing, Financial Services, E-commerce, Edtech, Space Exploration, Agriculture (Agri), and Cyber Security. Digital Health is the next frontier in this multi-sector revolution, requiring a unique lens for regulatory and security governance:

• Non-FDA Approved LLMs: It is a critical clinical reality that Large Language Models (LLMs) are currently not FDA approved (nor equivalently certified by CDSCO in India) for diagnostic or direct clinical decision-making. They serve as assistive tools, but the clinical liability remains human.
• Diagnostic Accuracy (The Doctor + AI Model): AI is essential for maximizing Diagnostic Accuracy, particularly in screening programs. For instance, Prof. Kshitij Jadhav highlighted a case study on AI-integrated Mammography for breast cancer screening. In India, where there is a high incidence of young breast cancer but no national screening program, a deep learning model was trained to highlight only suspicious lesions and calcifications.
• Synergy over Replacement: The optimal model remains “Doctor plus AI”. The human clinician provides context and nuance, while AI provides the high-velocity pattern recognition required for early detection. The goal is a collaborative synergy where AI acts as a decision-support assistant rather than an autonomous diagnostic “magic wand.”

---

Case Study: AI-Enhanced Triaging Workflow

To visualize why AI is critical for diagnostic accuracy, consider the transformation of the mammography screening workflow (Source: AIDE Lab / KCDH):

graph TD
    A[Patient Screening Mammogram] --> B{AI Risk Scoring}
    B -- "Low Risk" --> C[Streamlined Review]
    B -- "High Risk" --> D[Priority Double Reading]

    C --> E[Radiologist Validation]
    D --> F[Radiologist 1]
    D --> G[Radiologist 2]

    F --> H[Consensus]
    G --> H
    H -- Yes --> I[Final Diagnosis]
    H -- No --> J[Senior Radiologist Arbitration]
    J --> I
    E --> I

    style B fill:#e1f5fe,stroke:#01579b,stroke-width:2px
    style D fill:#ffebee,stroke:#b71c1c,stroke-width:2px

Figure: Shifting from standard linear review to AI-augmented triaging for optimized accuracy and workload.

• Standard Workflow (Before AI): Every scan follows a linear path—Radiologist 1 review, followed by Radiologist 2, with the third radiologist acting as an arbitrator only upon disagreement. This is resource-intensive and prone to “screening fatigue.”
• AI-Augmented Workflow: The AI system acts as a high-precision triage engine. Scans are assigned a Risk Score (1-10) based on suspicious lesions and calcifications.
  • Low-Risk Triaging: Scans with low scores (e.g., 1-5) follow a streamlined validation process.
  • High-Risk Prioritization: Scans with high scores (e.g., 6-10) are immediately prioritized for double-reading by specialized radiologists.
  • Optimized Recall: By adjusting thresholds, institutions can minimize false positives while ensuring every potential “hit” is captured, maximizing diagnostic accuracy while reducing clinician burden.

Indicator	Standard Workflow	AI-Augmented Workflow	Impact / Change
Reading Workload	100%	66.5%	-33.5% Reduction
Cancer Detection Rate	Baseline	Increased	Improved Screening Yield
False-Positive Rate	Baseline	Decreased	Reduced Patient Anxiety
Turnaround Time	Sequential	Prioritized	Faster High-Risk Results

Technical Deep Dive: The 4B vs. 1T Parameter Paradox

A critical insight shared during the sessions (Source: Prof. Kshitij Jadhav) centers on the efficiency of AI models in clinical settings.

• The Benchmarking Challenge: Modern LLMs with 1 trillion parameters (often based on massive open-source datasets) reach approximately 90% accuracy on medical benchmarks. However, these models are computationally expensive and difficult to deploy in low-resource clinical environments.
• Ontology-Augmented LLMs: By utilizing Medical Knowledge Graphs and Ontologies (like SNOMED CT) as structured context for LLMs, researchers have achieved a breakthrough in model efficiency.
• Superior Performance at Scale: A specialized 4 billion parameter model, when grounded in a medical knowledge hierarchy, achieves 88-90% accuracy—effectively matching the performance of models hundreds of times its size.
• Low-Resource Deployment: This “Knowledge-First” architecture is essential for India’s healthcare landscape, enabling high-precision AI to run on affordable hardware in rural hospitals and clinics where massive GPU clusters are unavailable.

Case Study: Predictive Survival & Triage (Poisoning Control)

Beyond screening, AI is a critical tool for scarce resource allocation. Prof. Kshitij Jadhav discussed a second high-impact use case: Predicting Survival in Rat Poison Ingestion.

graph LR
    A[Rat Poison Ingestion] --> B[Integrated Clinical Parameters]
    B --> C{AI Prediction Model}
    C -- "High Survival Probability" --> D[Supportive Care & Monitoring]
    C -- "Critical/Low Survival" --> E[Intensified Triage]
    E --> F[Acute Hemodialysis]
    E --> G[Liver Exchange Waitlist]

    subgraph "Accuracy: 80%"
    C
    end

• The Clinical Challenge: Patients who attempt suicide using rat poison often require intensive supportive therapy, dialysis, or a Liver Exchange.
• Resource Scarcity: India faces a severe shortage of liver donors, making it difficult to decide which patients should be prioritized for transplant vs. supportive therapy.
• The AI Solution: A predictive model was developed to triage these patients. By analyzing clinical parameters, the system achieved 80% accuracy in predicting survival outcomes. This allows clinicians to triage patients effectively, ensuring that high-resource interventions (like liver exchange) are directed where they have the highest probability of life-saving impact.

Case Study: Pan-Cancer Multimodal AI (Histogen)

The frontier of clinical AI lies in Multimodal integration—combining disparate data types for a single patient to enhance Predictive Survival analysis. Prof. Kshitij Jadhav presented the research on Pan-cancer Integrative Histology-Genomic Analysis (Source: Richard J. Chen et al. / AIDE Lab):

graph TD
    subgraph "Modality 1: Histopathology"
        H["High-Resolution Tissue Images<br/>(WSI)"] --> FE1["Feature Extraction<br/>(CNN/Transformer)"]
    end
    subgraph "Modality 2: Genomics"
        G["Molecular Sequences<br/>(NGS/VCF)"] --> FE2["Genomic Encoding"]
    end

    FE1 --> F["Multimodal Fusion Layer"]
    FE2 --> F

    F --> P["Predictive Neural Network"]
    P --> Out["<b>Predictive Foresight</b><br/>Distant Metastasis Prediction"]

    subgraph "Pan-Cancer Scope: Multiple Malignancies"
    Out
    end

    style F fill:#fff9c4,stroke:#fbc02d,stroke-width:2px
    style Out fill:#e8f5e9,stroke:#2e7d32,stroke-width:2px

Figure: Unified histology-genomic analysis architecture for cross-malignancy survival prediction.

To understand the complexity of this model, we must define the technical lexicon of modern oncology AI:

• Pan-cancer: Refers to the analysis of multiple different types of cancers simultaneously, identifying common survival patterns across diverse malignancies.
• Multimodal Data: The integration of more than one data modality—in this case, combining High-Resolution Histopathology Images (tissue structure) with Genomics Data (molecular sequences).
• Multimodal Neural Network: A sophisticated deep learning architecture specifically designed to ingest and process multiple data types simultaneously, fusing their insights into a single clinical output.
• Predictive Foresight: By leveraging this multimodal fusion, the model predicts the probability of Distant Metastasis across various cancer types, providing clinicians with a predictive window that single-modality systems cannot achieve.

Prof. Kshitij Jadhav further detailed the broader shifts in this space:

• The Shift to Open Source: The world of clinical AI is moving beyond classical localized CNNs. High-performance, Open Source Multimodal Models are emerging, such as Google’s Med-Gemma—a vision-language model that can process both clinical images and text instructions simultaneously.
• The Integration Benefit: A critical finding in multimodal research is that while analyzing Genomics or Histopathology in isolation may not show statistically significant prognostic differences, their Fusion (Integration) yields results that are highly significant. This mirrors how doctors actually function—never relying on a single test, but integrating clinical notes, images, and labs to reach a decision.
• Path to Personalized Medicine (The ‘Holy Grail’): AI is bridging the gap toward the long-promised goal of Personalized Medicine. A key project at Tata Memorial Hospital (TMH)—conducted in Multinational Collaboration with researchers in France and Russia—focuses on Hodgkin’s Lymphoma. The goal is to solve a critical clinical challenge: the administration of high-dosage cytotoxic chemotherapy without a definitive prediction of individual response.
  • Beyond Binary Diagnosis: While identifying Reed-Sternberg cells confirms a diagnosis of Hodgkin’s vs. Non-Hodgkin’s, researchers are now looking deeper into Whole Slide Images (WSI).
  • Cell-by-Cell Precision: By annotating slides cell-by-cell—identifying Lymphocytes, Neutrophils, Eosinophils, and Basophils—clinicians have fine-tuned open-source models to achieve 80-85% accuracy in cell identification.
• Informed Therapy Selection: This precision allows clinicians to map the Tumor Micro-environment, enabling the prediction of Therapy Response before treatment even begins. This is the “Holy Grail” of oncology—avoiding unnecessary toxicity and directing patients toward the most effective line of therapy from day one.

Decoding the Blueprint: The Role of Genomics & Epigenomics

A foundational pillar of research at KCDH involves understanding human diseases at their most basic level: the DNA, RNA, and the Epigenome.

Figure: The DNA Blueprint—Adenine (A), Thymine (T), Cytosine (C), and Guanine (G).

• The Foundation of Personalized Medicine: Personalized medicine is not just about the “average” patient; it is about tailoring treatment to the individual’s unique biological landscape. This approach depends heavily on the dual understanding of the Genome (the DNA sequence itself) and the Epigenome (the chemical modifications that control how genes are turned on or off).
• The Molecular Signature: Every disease leaves a signature at the molecular level. By studying the ATCG blueprint alongside epigenetic markers, researchers can identify the exact changes and regulatory shifts that drive specific human diseases.
• From Tangential to Central: While often seen as a specialized field, genomics and epigenomics are increasingly central to digital health. The ability to process and analyze these massive datasets allows for a level of Diagnostic and Therapeutic Precision that was previously impossible.
• Digital Health Integration: At KCDH, the focus is on bridging the gap between molecular research and clinical practice. Integrating these genomic and epigenetic “blueprints” into digital health platforms ensures that the patient’s individual biological reality is the primary driver of their longitudinal record.

Single-Cell Resolution: The Future of Precision Oncology

The frontier of genomic research at KCDH has moved beyond bulk tissue analysis to Single-Cell RNA Sequencing (scRNA-seq). This technology offers an unprecedented resolution into the cellular composition of tumors, allowing researchers to characterize disease at an individual cell level.

• The Methodology: Cellular Barcoding:
  • Dissociation: Tissue (e.g., from the liver or brain) is dissociated into individual cells that are physically separated.
  • Unique Identity: Each cell is assigned a unique barcode sequence. This barcode is attached to every RNA molecule extracted from that specific cell, ensuring that even after sequencing, the “molecular identity” of the cell is preserved.
  • mRNA Quantification (Poly-A Sequencing): The system captures mRNA molecules (identifiable by their poly-A tails), converts them to cDNA, and sequences them via high-throughput sequencers.
• The “Abundance of Differences” Principle:
  • Most physiological issues and disease progressions arise from an abundance of specific proteins or protein-producing sequences.
  • By comparing normal vs. cancerous samples, clinicians can quantify exactly how much mRNA each cell possesses, identifying the “abundance of differences” (transcriptomic shifts) that drive disease.
• Precision Targeting: Even within a single organ, cancer may only affect specific cell types. scRNA-seq allows researchers to pinpoint these exact cells among the trillions (36+ trillion) in the human body, avoiding the noise of “bulk” analysis.
• Viral Pathogen Detection: Using advanced algorithms, researchers can now extract Viral Pathogen data (e.g., HPV 16, 18, 54) from human-derived RNA sequences, even when the original assay wasn’t designed for it. Recent studies identified HPV 16 expression exclusively within specific clusters of infected cells.
• Reproducible Biomarkers: Because biological data is inherently noisy, KCDH develops advanced statistical models to denoise the data and transition from “one-off” observations to reproducible, clinical-grade biomarkers.

Case Study: Metabolic Associated Fatty Liver Disease (MAFLD)

Beyond oncology and acute poisoning, KCDH is addressing one of India’s most widespread yet silent health crises: Non-Alcoholic Fatty Liver Disease (NAFLD), increasingly referred to as Metabolic Associated Fatty Liver Disease (MAFLD).

• The Silent Epidemic: An estimated 1 in 3 individuals in India suffers from a fatty liver. Most cases remain undiagnosed because patients are often asymptomatic until the disease is advanced.
• The Diagnostic Gap: Current gold standards for diagnosis—Ultrasound and Fibroscan—are often reserved for symptomatic patients, leaving millions of early-stage cases undetected.
• The AI Goal: “Single-Drop” Diagnostics: The ultimate objective is to develop a diagnostic tool as simple as a glucose or HbA1c test. By identifying robust immune-system biomarkers in the blood that correlate with liver changes, KCDH aims to enable fatty liver detection from a single drop of blood.
• Overcoming Complexity: Immune changes in the liver are notoriously difficult to characterize. Standard methodologies often struggle with the non-reproducibility of biomarkers across different populations. KCDH is leveraging advanced AI algorithms to identify these elusive, reproducible markers, bridging the gap between clinical research and scalable screening.

Federated Learning: Collaboration Without Data Sharing

One of the most significant barriers to clinical AI is the “Data Silo” problem. Prof. Kshitij Jadhav introduced Federated Learning as the definitive solution for privacy-preserving collaboration:

• The Dilemma: Multiple hospitals have vast amounts of similar data, but regulatory and ethical barriers prevent them from sharing raw patient records with each other.
• The Architecture: In a Federated system, the raw data never leaves the hospital.

graph TD
    subgraph "Hospital A (Local)"
        DA["Raw Patient Data"] -.-> LA["Local Model A"]
    end
    subgraph "Hospital B (Local)"
        DB["Raw Patient Data"] -.-> LB["Local Model B"]
    end
    subgraph "Hospital C (Local)"
        DC["Raw Patient Data"] -.-> LC["Local Model C"]
    end
    subgraph "Central Aggregator"
        GM["<b>Global Federated Model</b>"]
    end

    LA -- "Model Parameters Only" --> GM
    LB -- "Model Parameters Only" --> GM
    LC -- "Model Parameters Only" --> GM

    GM -- "Optimized Learnings" --> LA
    GM -- "Optimized Learnings" --> LB
    GM -- "Optimized Learnings" --> LC

Figure: The Federated Learning loop—aggregating intelligence without moving raw data.

• Case Study: COVID-19 Triage: This approach was scaled for COVID-19 status prediction. By analyzing routine Vitals and Basic Blood Tests across diverse hospital ecosystems, the federated global model achieved significantly higher accuracy than any individual local model. By learning from the “diversity of scenarios” across institutions without ever seeing a single patient’s name, Federated Learning proves that privacy is not a barrier to, but a facilitator of, clinical excellence.

• Balancing AI & Judgment: Clinicians must balance AI-driven decision support with Clinical Judgment and Patient Preferences. AI should be viewed as an “informed second opinion,” where the final diagnostic and therapeutic word always rests with the human clinician and the patient’s individual autonomy.

• AI Cybersecurity Risks: Integrating public or non-standardized AI models introduces new attack vectors. Secure clinical AI requires private, HIPAA-compliant instances (VPCs) to ensure patient data never leaks into training sets or public domains.